Impact of TearCare on Reading Speed in Patients with Dry Eye Disease

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2024 Oct 15

PMID 39403710

Authors

Yilin Feng

Nandini Venkateswaran

Amanda Steele

Eric D Rosenberg

Preeya K Gupta

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the impact of TearCare (TC) treatment on clinical, quality of life, and functional visual outcome metrics in patients with dry eye disease (DED) and meibomian gland disease (MGD).

Methods: This is a prospective, single-center clinical trial. Adults with MGD and a DED diagnosis and tear break-up time (TBUT) <10 seconds were included. All subjects had at least 20/40 vision and no surgery or new treatment for DED within 60 days prior to enrollment. All patients had one baseline visit prior to undergoing TC and one follow-up visit 1 month after TC. At each visit, the meibomian gland secretion score (MGSS), TBUT, and corneal fluorescein staining (KFL) were assessed. DED symptoms were evaluated using the Ocular Surface Disease Index (OSDI) questionnaire, Visual Function Questionnaire 25 (VFQ-25), and the Fatigue Severity Scale. Reading speed was determined through the International Reading Speed Texts (IReST), Minnesota Low Vision Reading Test (MNREAD), and Wilkins Rate of Reading Test (WRRT).

Results: Thirty-two subjects were included. The average age was 55.9 years. Sixteen (52%) participants had a clinically significant improvement in reading speed after treatment with TC, defined as >10 words per minute increase in their IReST score. Improvement on the IReST and the MNREAD reached statistical significance (p = 0.012 and p = 0.028, respectively). OSDI scores significantly decreased and VFQ-25 scores significantly increased after TC treatment (p < 0.001). All of the clinical exam parameters showed statistically significant improvements after treatment (p < 0.001).

Conclusion: TC is an effective treatment both clinically and with respect to visual function. Patients who had TC exhibited improvements in quality of life and improved reading speed after a single treatment. This treatment should be frequently considered and utilized to reduce the disease burden of DED related to MGD.

References

Trauzettel-Klosinski S, Dietz K . Standardized assessment of reading performance: the New International Reading Speed Texts IReST. Invest Ophthalmol Vis Sci. 2012; 53(9):5452-61. DOI: 10.1167/iovs.11-8284. View

Gupta P, Holland E, Hovanesian J, Loh J, Jackson M, Karpecki P . TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. Cornea. 2021; 41(4):417-426. PMC: 8895971. DOI: 10.1097/ICO.0000000000002837. View

Pflugfelder S . Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008; 14(3 Suppl):S102-6. View

Rabensteiner D, Aminfar H, Boldin I, Schwantzer G, Horwath-Winter J . The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol. 2018; 96(6):e707-e711. PMC: 6619403. DOI: 10.1111/aos.13732. View

Jaeschke R, Singer J, Guyatt G . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10(4):407-15. DOI: 10.1016/0197-2456(89)90005-6. View

Yu J, Asche C, Fairchild C . The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2010; 30(4):379-87. DOI: 10.1097/ICO.0b013e3181f7f363. View

McDonald M, Patel D, Keith M, Snedecor S . Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. Ocul Surf. 2016; 14(2):144-67. DOI: 10.1016/j.jtos.2015.11.002. View

Szczotka-Flynn L, Maguire M, Ying G, Lin M, Bunya V, Dana R . Impact of Dry Eye on Visual Acuity and Contrast Sensitivity: Dry Eye Assessment and Management Study. Optom Vis Sci. 2019; 96(6):387-396. PMC: 6544497. DOI: 10.1097/OPX.0000000000001387. View

Ousler 3rd G, Rodriguez J, Smith L, Lane K, Heckley C, Angjeli E . Optimizing Reading Tests for Dry Eye Disease. Cornea. 2015; 34(8):917-21. DOI: 10.1097/ICO.0000000000000490. View

10.

Bitton E, Lacroix Z, Leger S . In-vivo heat retention comparison of eyelid warming masks. Cont Lens Anterior Eye. 2016; 39(4):311-5. DOI: 10.1016/j.clae.2016.04.002. View

11.

Holland E, Loh J, Bloomenstein M, Thompson V, Wirta D, Dhamdhere K . A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease. Clin Ophthalmol. 2022; 16:2861-2871. PMC: 9440678. DOI: 10.2147/OPTH.S368319. View

12.

Miller K, Walt J, Mink D, Satram-Hoang S, Wilson S, Perry H . Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010; 128(1):94-101. DOI: 10.1001/archophthalmol.2009.356. View

13.

Ayres B, Bloomenstein M, Loh J, Chester T, Saenz B, Echegoyen J . A Randomized, Controlled Trial Comparing Tearcare and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clin Ophthalmol. 2023; 17:3925-3940. PMC: 10741761. DOI: 10.2147/OPTH.S442971. View

14.

Chuckpaiwong V, Nonpassopon M, Lekhanont K, Udomwong W, Phimpho P, Cheewaruangroj N . Compliance with Lid Hygiene in Patients with Meibomian Gland Dysfunction. Clin Ophthalmol. 2022; 16:1173-1182. PMC: 9034837. DOI: 10.2147/OPTH.S360377. View

15.

Xiong Y, Calabrese A, Cheong A, Legge G . Reading Acuity as a Predictor of Low-Vision Reading Performance. Invest Ophthalmol Vis Sci. 2018; 59(12):4798-4803. PMC: 6181187. DOI: 10.1167/iovs.18-24716. View

16.

Blackie C, Solomon J, Greiner J, Holmes M, Korb D . Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008; 85(8):675-83. DOI: 10.1097/OPX.0b013e318181adef. View

17.

Wilkins A, Jeanes R, Pumfrey P, Laskier M . Rate of Reading Test: its reliability, and its validity in the assessment of the effects of coloured overlays. Ophthalmic Physiol Opt. 1996; 16(6):491-7. View

18.

Ridder 3rd W, Zhang Y, Huang J . Evaluation of reading speed and contrast sensitivity in dry eye disease. Optom Vis Sci. 2012; 90(1):37-44. DOI: 10.1097/OPX.0b013e3182780dbb. View

19.

Borchman D . The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf. 2019; 17(2):360-364. PMC: 6529265. DOI: 10.1016/j.jtos.2019.02.005. View

20.

Findlay Q, Reid K . Dry eye disease: when to treat and when to refer. Aust Prescr. 2018; 41(5):160-163. PMC: 6202299. DOI: 10.18773/austprescr.2018.048. View